Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study

View/ Open
Access
info:eu-repo/semantics/embargoedAccessDate
2022Author
Bilici, AhmetUysal, Mükremin
Menekşe, Serkan
Akın, Semih
Yıldız, Fatih
Turan, Merve
Sezgin Göksu, Sema
Beypınar, İsmail
Sakalar, Teoman
Değirmenci, Mustafa
Erdem, Dilek
Başaran, Gül
Ölmez, Ömer Fatih
Avcı, Nilüfer
Tural, Deniz
Sakin, Abdullah
Türker, Sema
Demir, Atakan
Temiz, Süleyman
Kaplan, Muhammed Ali
Doğan, Mutlu
Tanrıverdi, Özgür
Bilgetekin, İrem
Yeşil Çınkır, Havva
Açıkgöz, Özgür
Paydaş, Semra
Uslu, Rüçhan
Turhal, Serdar
Metadata
Show full item recordCitation
Bilici, A., Uysal, M., Menekşe, S., Akın, S., Yıldız, F., Turan, M. ... Turhal, S. (2022). Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study. Cancer Investigation, 40(2), 199-209. https://dx.doi.org/10.1080/07357907.2021.2017952Abstract
Purpose: This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) metastatic breast cancer (MBC) patients in real-life settings. Methods: Overall, 204 HR+, HER2− MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed. Results: The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). The presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001). Conclusion: We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER − MBC patients.
WoS Q Kategorisi
Q4xmlui.dri2xhtml.METS-1.0.item-scopusquality
Q2Source
Cancer InvestigationVolume
40Issue
2Collections
- Makale Koleksiyonu [3454]
- PubMed İndeksli Yayınlar Koleksiyonu [3772]
- Scopus İndeksli Yayınlar Koleksiyonu [5815]
- WoS İndeksli Yayınlar Koleksiyonu [5982]